System1 combines next-generation patient-derived organoid models, scaled biology and machine learning to discover new treatments for brain disorders. The company uses a vertically-integrated cloud-based drug discovery plaftorm called ORCA to target diseases through drug screening and analysis of multi-modal data including microscopy, functional neural dynamics, immunoflourescent imaging and transcriptomics.
Presented by Doug Flanzer, CTO, System1Bio
